Fat consumption in western society has increased dramatically throughout the course of the twentieth century. As a consequence, coronary heart disease is now the most common cause of death from middle age onwards in much of the developed world. Yet trials have shown that lipid-lowering drugs can decrease the risk of coronary heart disease and stroke, and increase life expectancy. Using an evidence-based approach this illustrated guide offers practical solutions to the problems encountered by healthcare professionals in the clinical management of hyperlipidaemia.
18 pages matching occur in this book
Results 1-3 of 18
What people are saying - Write a review
We haven't found any reviews in the usual places.
5.0 mmol/litre adipose tissue alcohol apolipoprotein atherogenic atheroma atherosclerosis carbohydrate CHD risk cholesterol and triglycerides cholesterol concentration cholesteryl ester chylomicrons circulation clinical trials coronary disease decrease dense LDL diet dietary effect elevated enzyme familial combined hyperlipidaemia fatty acids fibrates fibrous cap Figure foam cells free cholesterol HDL cholesterol HDL TC hepatic heterozygotes heterozygous FH homozygotes homozygous FH hyper hypercholesterolaemia hyperlipidaemia hyperlipoproteinaemia hypertension important insulin resistance laboratory LDL lowering LDL receptor lesions lipid liver low HDL cholesterol Lp(a macrophages mmol/litre 200 mg/dl myocardial infarction NEFA nicotinic acid normal obesity occur oxidation particularly patients with hypertriglyceridaemia phospholipids plasma polygenic polygenic hypercholesterolaemia primary prevention protein reduced renal disease result risk factors secondary hyperlipidaemia secondary prevention Serum HDL cholesterol severe hypertriglyceridaemia statin therapy statins syndrome tendon xanthomata total cholesterol treatment triglyceride-rich lipoproteins triglycerides Type 2 diabetes type III hyperlipoproteinaemia vascular disease VLDL VLDL and LDL VLDL secretion women xanthomata